Skip to content

Co-stimulatory and -inhibitory molecules on tumor-infiltrating lymphocytes from cholangiocarcinoma

Co-stimulatory and -inhibitory molecules on tumor-infiltrating lymphocytes from cholangiocarcinoma - Co-stimulatory and -inhibitory molecules in CCA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON43309
Enrollment
102
Registered
2016-08-15
Start date
2016-09-01
Completion date
Unknown
Last updated
2026-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

bile duct cancer cholangiocarcinoma

Interventions

None listed

Sponsors

Stichting Leveronderzoek
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: Adult cholangiocarcinoma (CCA) patients that will undergo surgery for this disease.

Exclusion criteria

Exclusion criteria: Patients who refuse blood donation/participation in the study Patients with a severe immunocompromised condition, or patients taking immunosuppressive medication

Design outcomes

Primary

MeasureTime frame
The main study parameters are: 1) Frequencies and absolute cell counts of different lymphocyte populations that together compose the tumor-infiltrating lymphocyte pool. 2) Expression of co-stimulatory/co-inhibitory molecules on TIL vs lymphocytes isolated from tumor-free liver tissue vs circulating lymphocytes 3) Effect of blocking co-inhibitory molecules or stimulating co-stimulatory molecules expressed by TIL on their function (proliferation and cytokine production) in ex vivo co-culture experiments

Secondary

MeasureTime frame
Depending on the co-inhibitory molecules detected on TIL, immunohistochemistry will be performed on residual formalin-fixed paraffin-embedded tumor tissue that is regularly stored to identify the expression of the ligands of these co-inhibitory molecules (for instance PDL1+2 and GAL9) on tumor (infiltrating) cells.

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP) · Data processed: Jun 21, 2026